Pharsight

Vanos generic

Vanos, an anti-inflammatory drug owned by Bausch, contains the active ingredient fluocinonide. The drug received market authorization on February 11, 2005, and has held a total of 3 patents.

When will Vanos generic be available?

The generic versions of Vanos are likely to hit the market after March 9, 2023. This is due to the expiration of the last patent, US8232264, on that date.

Vanos uses

Vanos is extensively used for relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. The active ingredient, fluocinonide, contributes significantly to this effect.

Vanos patent expiration

Vanos, with Fluocinonide as its active ingredient, has 3 patents. The last patent, US8232264 titled 'Compositions and methods for enhancing corticosteroid delivery', is due to expire on March 9, 2023. Hence, any Vanos generic could be available following this date. Below are the details of the patents:

Vanos dosage

Want to ask something?